Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population

Between 2003 and 2016, transmitted HIV-1 drug resistance has increased in a large California clinic population. However, the most commonly transmitted drug-resistance mutations reduce susceptibility primarily to drugs that are no longer frequently used.

[1]  Philip L. Tzou,et al.  Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation , 2017, PloS one.

[2]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[3]  L. Saiman,et al.  A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Aris-Brosou,et al.  Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. , 2012, The Journal of infectious diseases.

[5]  Michael I. Jordan,et al.  E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. , 2014, Antiviral research.

[6]  O. Gascuel,et al.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK , 2015, AIDS.

[7]  M. Weinstein,et al.  Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Morris,et al.  Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[9]  Sergei L. Kosakovsky Pond,et al.  Not so different after all: a comparison of methods for detecting amino acid sites under selection. , 2005, Molecular biology and evolution.

[10]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[11]  A. Rambaut,et al.  BEAST: Bayesian evolutionary analysis by sampling trees , 2007, BMC Evolutionary Biology.

[12]  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity , 2014, Retrovirology.

[14]  W. Duffus,et al.  Transmitted Antiretroviral Drug Resistance in Individuals with Newly Diagnosed HIV Infection: South Carolina 2005–2009 , 2011, Southern medical journal.

[15]  Beda Joos,et al.  Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  E. Overton,et al.  Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. , 2012, AIDS Research and Human Retroviruses.

[17]  Jerome H. Kim,et al.  Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis , 2015, PLoS medicine.

[18]  K. White,et al.  Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide , 2017, The Journal of infectious diseases.

[19]  V. van Eygen,et al.  96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials , 2013, Antiviral therapy.

[20]  R. Haubrich,et al.  Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load , 2011, PloS one.

[21]  S. Little,et al.  No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men , 2017, Journal of Virology.

[22]  D. Webster,et al.  Persistence of HIV-1 Transmitted Drug Resistance Mutations , 2013, The Journal of infectious diseases.

[23]  Huldrych F. Günthard,et al.  Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration , 2017, EBioMedicine.

[24]  Samantha Lycett,et al.  Automated analysis of phylogenetic clusters , 2013, BMC Bioinformatics.

[25]  P. Harrigan,et al.  Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[27]  D. Richman,et al.  Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996–2013 , 2016, Journal of acquired immune deficiency syndromes.

[28]  F. Hecht,et al.  Differential persistence of transmitted HIV-1 drug resistance mutation classes. , 2011, Journal of Infectious Diseases.

[29]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[30]  A. von Haeseler,et al.  IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies , 2014, Molecular biology and evolution.

[31]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Huldrych F. Günthard,et al.  Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds , 2015, PLoS pathogens.

[33]  H. Günthard,et al.  Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Katzenstein,et al.  Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  H. Masur,et al.  Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014 , 2017, BMC Research Notes.